EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)
Phase of Trial: Phase III
Latest Information Update: 18 Jul 2016
At a glance
- Drugs Lorazepam (Primary)
- Indications Generalised anxiety disorder
- Focus Registrational; Therapeutic Use
- Sponsors Edgemont Pharmaceuticals
- 14 Jul 2016 Status changed from recruiting to completed.
- 20 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 07 Jan 2015 Planned initiation date changed from 1 Dec 2014 to 1 Jan 2015, as reported by ClinicalTrials.gov.